Evaluation of the NEOmom® Gastric Video Capsule for Gastric Cancer Screening

Gastric cancer remains a major public health concern, with approximately 6,600 new cases diagnosed each year in France. Despite therapeutic progress, its overall prognosis is still poor: the 5-year survival rate across all stages remains below 30%. This survival is closely linked to the stage at diagnosis. Early-stage gastric cancer has an excellent prognosis, with survival rates above 90%, while advanced-stage disease shows survival below 10%. This dramatic contrast underscores the critical need to develop and implement approaches that enable earlier and more reliable diagnosis. Early detection is therefore one of the most powerful strategies to reduce mortality from this severe and often silent disease. Within this context, the overall ambition of the NEOTOGAS project is to contribute to lowering gastric-cancer mortality by improving the ability to diagnose the disease at an early, more treatable stage. The project positions itself within the broader field of prevention, targeting one of the leading and most challenging public health issues. Gastric cancer is often a potentially fatal condition that typically develops over many years, most commonly as a consequence of chronic infection with Helicobacter pylori (H. pylori). Identifying precancerous gastric lesions before the appearance of invasive cancer thus represents a strategic priority for the healthcare system. Our central hypothesis is that a non-invasive, robot-assisted endoscopic approach using a magnetic-guided capsule-the NEOMOM system-will prove effective for detecting precancerous gastric lesions. If validated, this technology could form the foundation of an organized, large-scale screening program. Such a screening strategy would represent a major innovation, particularly in populations at higher risk due to H. pylori infection or other predispositions. The ability to offer a less invasive, more accessible examination could significantly increase screening adherence and facilitate earlier diagnosis. The NEOTOGAS study is based on an innovative combination of technologies: a magnetic-guided videocapsule steered inside the stomach using the NEOMOM robot, supported by artificial intelligence to assist image acquisition and interpretation. The study aims to assess the level of concordance between lesion detection through the current gold-standard procedure (conventional endoscopy) and this new capsule-based examination. Beyond diagnostic performance, the project also integrates several essential dimensions for future implementation: patient acceptability of the procedure, overall cost, duration of the examination, and the potential clinical and organizational benefits of this alternative approach. A key component of the project is the creation of high-quality image banks. These will support the development of advanced AI models capable of enhancing lesion detection and ensuring the completeness of the stomach examination. Such resources will be instrumental in evaluating whether magnetic-guided capsule endoscopy could realistically be integrated into structured gastric cancer screening pathways in the future. The project therefore aims not only to evaluate a device, but also to explore its broader screening potential and its capacity to transform clinical practice. The primary objective of the NEOTOGAS study is to rigorously assess the performance of this innovative medical device, which combines magnetic navigation with AI-assisted image interpretation, in detecting gastric lesions. The AI module plays a dual role: ensuring that the entire stomach is adequately explored and helping highlight images of interest for clinicians during analysis. By improving both completeness and accuracy, the technology could represent a significant advancement over existing non-invasive diagnostic tools. To achieve these goals, the study plans to include a total of 100 patients over a 6-month period. This sample size will allow a robust comparison of diagnostic concordance while providing sufficient data to evaluate feasibility, patient experience, and operational parameters. The findings of NEOTOGAS will determine whether magnetic-guided capsule endoscopy can be considered a relevant and effective method for future organized gastric cancer screening programs.

Sex

All

Minimum age

50 Years

Maximum age

74 Years

Inclusion Criteria:

* Male or female patient,
* Aged between 50 and 74 inclusive with a life expectancy of at least 10 years,
* Undergoing screening or surveillance colonoscopy (for colorectal cancer or polyps)
* Patient who has received verbal and written information as well as a patient booklet on the VCE-CM examination and has given their written informed consent.
* Patient affiliated with a social security scheme
* Effective contraception throughout the study for women of childbearing age

Exclusion Criteria:

* Patients who have had or currently have the following (items from the TOGAS pilot study/specific to endoscope use) will not be included in the study:
* An EOGD in a high-volume endoscopy centre within the last 3 years
* Known gastric cancer
* Known genetic cancer syndromes
* Previous gastrectomy or bariatric gastric surgery
* Known gastric precancerous condition (gastric atrophy, intestinal metaplasia, dysplasia)
* Acute gastrointestinal haemorrhage in the last 4 weeks
* A coagulation disorder or medication that prevents biopsy sampling
* A risk associated with sedation or anaesthesia
* Severe heart disease
* An inability to actively consent to participation in the study, and patients under guardianship or legal protection.

Pregnant or breastfeeding patients will not be included.

Patients with the following conditions (specific to VCE-CM examination) will not be included in the study:

* Swallowing disorders or known gastroparesis
* A history of digestive surgery
* Clinical or radiological signs suggestive of narrowing of the digestive tract
* An occlusive or sub-occlusive condition, a known or suspected history of stenosis or digestive fistula
* Left heart failure with orthopnoea
* Overweight (\> 135 kg)
* Reduced mobility (i.e. unable to transfer or move themselves)
* Persons with pacemakers, defibrillators or metallic foreign bodies (with the exception of dental implants) will not be included in order to avoid interference with the robot.